Having trouble accessing articles? Reset your cache.

Product Development
COVID-19 roundup: Qiagen ships diagnostic to China; plus Gilead starts own remdesivir trials and Ascletis clinical update

Qiagen said Wednesday it is seeking emergency FDA clearance for its coronavirus diagnostic. Separately, Gilead started a pair of Phase III trials of remdesivir to treat COVID-19, ...

Subgroup analyses help Vanda hold steady despite Phase III itch miss

Vanda shares Wednesday mostly shrugged off a sharp decline in after-hours trading Tuesday after tradipitant missed the primary endpoint in the Phase III EPIONE trial to treat ...

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

Takeda gains another celiac candidate via PvP takeout

After PvP Biologics Inc. finished a Phase I trial demonstrating proof of concept of its celiac disease therapy, ...

Emerging Company Profile
WindMIL: T cell source is key

WindMIL is developing cancer therapies using bone marrow-derived T cells, which could be more persistent than tumor-infiltrating lymphocytes and hit a broader range of antigens ...

Politics, Policy & Law
China moves to improve academic research quality, promote translational research

As China responds to the COVID-19 outbreak, the country’s ministries of Science and Technology and Education have issued guidance that aims to reduce of the focus of academic ...

BioCentury ISSN 1097-7201